HomePhilippine Scientific Journalvol. 52 no. 1 (2019)

Intrauterine Fetal Blood Transfusion in Hemoglobin Bart’s Hydrops Fetalis Syndrome

Maria Angelica T. Gamo | Angelita R. Teotico

 

Abstract:

Hemoglobin Barts syndrome, or alpha-thalassemia major, is a rare but fatal syndrome that results from the deletion of all four genes of the alpha-globin loci. Due to the poor prognosis of the disease with no known definitive interventions, patients and their spouses with a fetus diagnosed with hydrops fetalis have often elected for pregnancy termination. Newer studies show that in utero fetal transfusion have led to improvements in perinatal management and outcomes of patients with fetal Hemoglobin Barts disease, providing a possible viable option for patients who are prenatally diagnosed with fetal alpha-thalassemia major. This paper presents a case of a 19-year-old primigravid who was referred to our institution at 28 3/7 weeks age of gestation for sonographic findings of double outlet right ventricle and was later diagnosed with hydrops fetalis. The patient and her spouse underwent work-up and were both found to be alpha-thalassemia carriers. On peripheral blood smear, the fetus was found to have microcytic, hypochromic red blood cells, with spherocytosis, poikilocytosis, and anisocytosis. She underwent two courses of in utero fetal transfusion. At 31 1/7 weeks age of gestation, the patient showed a non-reassuring fetal pattern consisting of persistent late decelerations on fetal heart monitoring. She underwent emergency cesarean section and delivered subsequently to a weak baby of ambiguous gender. The newborn expired shortly after. This paper aims to improve awareness and knowledge with regards to current management of pregnant patients diagnosed with hydrops fetalis arising from Hemoglobin Barts disease appropriate for our setting.



References:

  1. Kumar V, Abbas AK, Aster JC. Robbins and Cotran Pathologic Basis of Disease. 9th Ed. Philadelphis: Elsevier Saunders; 2015. 638p.
  2. Javier MJ, Cheng MR, Abat MA. Beating the odds: A case report on the successful management of a non-immune hydrops fetalis due to hemoglobin Bart’s disease. PJOG. 2016 Jul-Sep;40(3):23-28.
  3. Creasy RK, Resnik R, Iams JD, Lockwood CJ, Moore TR, Greene MF. Creasy and Resnik’s Maternal-Fetal Medicine. 7th Ed. Philadelphia: Elsevier Saunders; 2014. 563-64 p.
  4. The Society of Obstetricians and Gynaecologists of Canada. Investigation and Management of Non-Immune Fetal Hydrops. J Obstet Gynaecol Can. 2013 Oct; 35(10): e1-14.
  5. Divya-Devi J, Nickerson HJ, and McManus MJ. Hydrops Fetalis Caused by Homozygous α-Thalassemia and Rh Antigen Alloimmunization. Clin Med Res. 2004 Oct 22;2(4):228-32.
  6. Vichinsky, EP. Alpha thalassemia major-new mutations, intrauterine management, and outcomes. Am Soc Hema. 2009 Jan 1;2009(1):35-41.
  7. Kreger EM, Singer ST, Witt RG, Sweeters N, Lianoglou B, Lal A, et al. 2016. Favorable outcomes after in utero transfusion in fetuses with alpha thalassemia major: a case series and review of the literature. Prenat Diagn. 2016 Dec;36(13): 1242-49.
  8. Medscape [Internet]. Medscape; 2017 Jul 25. Pediatric Hydrops Fetalis Treatment and Management; [updated 2017 Jul 25; cited 2018 May 4]. Available from: https://emedicine.medscape.com/article/974571-treatment
  9. Songdej D, Babbs C, and Higgs DR. An international registry of survivors with Hb Bart’s hydrops fetalis syndrome. Blood. 2017 March 9;129(10): 1251-59.
  10. Babaei M, Shafiei S, Bijani A, Heidari B, Hosseyni SR, and Sadeghi MV. Ability of serum ferritin to diagnose iron deficiency anemia in an elderly cohort. Rev Bras Hematol Hemoter. 2017 Jul-Sep; 39(3): 223-228.